This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Tiziana Life Sciences to Showcase Intranasal Foralumab Progress at Jefferies Healthcare Conference

Tipranks - Tipranks - Fri May 29, 6:52AM CDT

Memorial Day Sale – Claim 70% Off TipRanks

Tiziana Life Sciences ( (TLSA) ) has shared an update.

On May 28, 2026, Tiziana Life Sciences said it will present at the Jefferies Healthcare Conference in New York, with CEO Ivor Elrifi and COO/CFO Keeren Shah set to deliver a corporate update on June 4, 2026. The session, followed by a Q&A with institutional investors, will spotlight recent clinical and corporate developments, underscoring the company’s efforts to advance its lead program, intranasal foralumab, and communicate strategic milestones to the market.

The company highlighted ongoing work with intranasal foralumab, including dosing 14 patients with non-active secondary progressive multiple sclerosis in an expanded access program and running a Phase 2a dose-ranging trial in the same indication. These developments position Tiziana as a differentiated player in neuroinflammatory and neurodegenerative disease treatment, and the Jefferies appearance provides a platform to reinforce its profile with investors as it progresses multiple clinical programs.

The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on immunotherapy delivered through alternative routes, notably intranasal administration. Its lead asset, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development and is being advanced for neuroinflammatory and neurodegenerative diseases, supported by a patent-backed drug delivery platform with broader pipeline potential.

Tiziana’s nasal delivery strategy aims to improve efficacy, safety, and tolerability versus traditional intravenous approaches, with foralumab demonstrating a favorable safety profile and clinical responses in studies to date.

Average Trading Volume: 183,667

Technical Sentiment Signal: Strong Buy

Current Market Cap: $179.5M

Learn more about TLSA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).